Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28087484 | 0.60 | — | — | |
| SCHEMBL9077587 | 0.56 | CFTR (0.37) | KDM4ELMNAALDH1A1KMT2A | |
| Biphenyl SCHEMBL3399859 | 0.56 | ALDH1A1 (0.60) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL29282085 | 0.56 | ALDH1A1 (0.60) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL5071211 | 0.56 | ALDH1A1 (0.60) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL7062651 | 0.56 | ALDH1A1 (0.60) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL1396421 | 0.55 | ALDH1A1 (0.69) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL750993 | 0.55 | ALDH1A1 (0.69) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL190337 | 0.55 | ALDH1A1 (0.69) | TP53LMNAALDH1A1 | |
| Biphenyl SCHEMBL377457 | 0.55 | ALDH1A1 (0.69) | TP53LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | TP53 156/4885PIN1 807/4885KDM4E 1519/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | TP53 170/4885PIN1 1050/4885KDM4E 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.